4.1 Tricyclic and Cyclic Antidepressants: Cardiotoxicity, ECG Findings, and Bicarbonate Therapy

Tricyclic antidepressants (TCAs) and related cyclic compounds—including amitriptyline, nortriptyline, imipramine, doxepin, clomipramine, desipramine, and the tetracyclic maprotiline—remain among the most lethal prescription ingestions encountered in clinical toxicology and poison center operations. Although newer antidepressants have largely superseded TCAs for uncomplicated depression, TCAs are widely prescribed for neuropathic pain, migraine prophylaxis, fibromyalgia, and obsessive-compulsive disorder. In acute overdose, their narrow therapeutic window and multi-receptor pharmacology generate rapid-onset, life-threatening cardiovascular and neurological toxicity.

---

Multi-Receptor Pharmacology and Pathophysiology

The clinical syndrome of cyclic antidepressant poisoning cannot be explained by a single pharmacological action. Instead, it reflects competitive antagonism across at least six distinct receptor populations and ion channels. Understanding each target explains the complex constellation of clinical manifestations and guides targeted resuscitation.

---

Electrophysiological Cardiotoxicity and ECG Hallmarks

The hallmark of cyclic antidepressant cardiotoxicity is the blockade of cardiac fast sodium channels (Nav1.5) in the His-Purkinje system and ventricular myocardium. By slowing Phase 0 depolarization, TCAs dramatically decrease the maximum rate of cardiac action potential upstroke (Vmax). This delays intraventricular conduction, manifesting on the surface 12-lead electrocardiogram (ECG) as progressive widening of the QRS complex and distortion of the terminal portion of the ventricular depolarization vector.

1. Sinus Tachycardia

Sinus tachycardia (heart rate > 100 bpm) is typically the earliest and most consistent electrocardiographic sign of TCA toxicity. It results from a dual mechanism: potent muscarinic (M2) blockade removing vagal tone at the sinoatrial node, coupled with inhibition of presynaptic norepinephrine reuptake prolonging sympathetic stimulation. The absence of sinus tachycardia in a suspected severe TCA ingestion should prompt immediate evaluation for co-ingestants (e.g., beta-blockers, calcium channel blockers, clonidine) or impending conduction system failure.

2. QRS Interval Prolongation and Prognostic Thresholds

In their landmark clinical investigation, Boehnert and Love established the critical predictive value of QRS duration in acute tricyclic antidepressant poisoning:

• QRS < 100 milliseconds (ms): Low risk for critical cardiovascular or central nervous system complications.
• QRS >= 100 ms: Strongly correlates with neurotoxicity; approximately 34% of patients develop generalized seizures.
• QRS >= 160 ms: Strongly correlates with severe cardiotoxicity; approximately 50% of patients develop life-threatening ventricular dysrhythmias (monomorphic ventricular tachycardia, ventricular fibrillation, or conduction arrest).

3. Terminal 40-Millisecond Rightward Axis Deviation (T40ms)

Because the right bundle branch and right ventricular outflow tract (RVOT) are anatomically vulnerable to conduction delay, the terminal 40 milliseconds of ventricular depolarization shifts superiorly and to the right. This electrophysiological phenomenon produces characteristic diagnostic morphology in leads aVR, I, and aVL:

• Lead aVR: A prominent, wide terminal positive deflection (R wave) measuring >= 3 mm in amplitude, or a terminal R-to-S ratio (R/S) > 0.7.
• Leads I and aVL: Deep, slurred terminal negative deflections (S waves).

These findings in lead aVR frequently precede marked QRS widening and provide high sensitivity and specificity for fast sodium channel blockade, alerting the poison specialist to imminent clinical deterioration even when the total QRS duration appears borderline.

---

Targeted Pharmacotherapy: IV Sodium Bicarbonate

Intravenous hypertonic sodium bicarbonate (8.4% NaHCO3) is the specific and established first-line antidote for cyclic antidepressant cardiotoxicity. It operates through two distinct, synergistic physiological mechanisms.

Dual Mechanism of Action

1. Sodium Load Effect: Administration of hypertonic sodium increases the extracellular sodium concentration (8.4% NaHCO3 contains 1,000 mEq/L of Na+). This steepens the chemical gradient across myocardial cell membranes, overcoming the competitive, voltage-dependent fast sodium channel blockade by sheer mass action and displacing TCA molecules from channel binding sites.
2. Alkalinization Effect: Elevating the extracellular blood pH from an acidemic or normal level to a target of 7.50 to 7.55 shifts the equilibrium of cyclic antidepressants toward their uncharged, unionized (lipophilic) state. Only the protonated, charged cationic form of the drug binds with high affinity to the Nav1.5 receptor; alkalinization causes the drug to dissociate rapidly from the receptor, restoring normal Phase 0 conduction velocity.

Clinical Indications for Sodium Bicarbonate

• QRS duration > 100 ms on any 12-lead ECG.
• Terminal R wave in aVR >= 3 mm or R/S ratio in aVR > 0.7.
• Ventricular dysrhythmias (monomorphic ventricular tachycardia, wide-complex tachycardia, ventricular fibrillation).
• Hypotension refractory to volume expansion with isotonic crystalloids.
• Severe metabolic acidosis (arterial blood pH < 7.20) secondary to hypoventilation or seizures.

Dosing and Administration Protocol

• Initial Push Bolus: Administer 1 to 2 mEq/kg of 8.4% sodium bicarbonate (typically one to two 50-mL adult prefilled syringes containing 50 mEq each) as a rapid intravenous push over 1 to 2 minutes.
• Reassessment: Obtain an immediate post-bolus ECG. Narrowing of the QRS complex and hemodynamic improvement are typically visible within 2 to 5 minutes.
• Repeat Boluses: If QRS widening persists (>100 ms) or hemodynamic instability continues, repeat boluses of 1 to 2 mEq/kg every 3 to 5 minutes until electrophysiological improvement is achieved or arterial pH reaches 7.55.
• Continuous Maintenance Infusion: Once the patient is stabilized, initiate a continuous infusion to maintain systemic alkalemia. Mix 150 mEq of sodium bicarbonate (three 50-mL ampules of 8.4% NaHCO3) in 1,000 mL of 5% Dextrose in Water (D5W) to yield an approximately isotonic solution (~150 mEq/L). Infuse at 150 to 250 mL/hour (2 to 3 times maintenance rate).
• Monitoring Endpoints and Safety Limits: Serial blood gas analysis every 1 to 2 hours is required. Target an arterial pH of 7.50 to 7.55 and a serum bicarbonate concentration of 30 to 32 mEq/L. Terminate or down-titrate the infusion if arterial blood pH exceeds 7.55, as severe alkalemia precipitates hypocalcemic tetany, cerebral vasoconstriction, and ventricular dysrhythmias.
• Potassium Repletion: Alkalinization drives extracellular potassium into myocytes via hydrogen-potassium exchange, causing rapid hypokalemia. Hypokalemia impairs resting membrane potential and impedes sodium channel reactivation. Serum potassium must be aggressively monitored and supplemented to maintain a target of 4.0 to 4.5 mEq/L (e.g., adding 20–40 mEq KCl per liter of infusion once urine output is confirmed).

Role of Hypertonic Saline (3% NaCl)

If the patient remains hemodynamically unstable or exhibits wide-complex dysrhythmias despite reaching the upper pH limit of 7.55, further sodium bicarbonate is contraindicated. In this scenario, 3% Hypertonic Saline (100 to 200 mL IV bolus) should be administered. Hypertonic saline delivers a concentrated sodium ion load to overcome Nav1.5 channel blockade without inducing further systemic alkalinization.

---

Hemodynamic Collapse and Vasopressor Selection

Hypotension in cyclic antidepressant toxicity arises from a combination of myocardial contractility depression (from intracellular calcium handling impairment and sodium channel blockade) and marked peripheral vasodilation (from vascular alpha-1 adrenergic receptor blockade).

Resuscitation Hierarchy

1. Volume Expansion: Administer initial rapid fluid boluses of 10 to 20 mL/kg of isotonic crystalloid (normal saline or lactated Ringer's). Volume repletion must be balanced against the risk of pulmonary edema in patients receiving large sodium bicarbonate volumes.
2. Sodium Bicarbonate: Boluses must be co-administered, as overcoming sodium channel blockade frequently restores myocardial inotropy and blood pressure.
3. Vasopressor of Choice — Norepinephrine: If hypotension persists despite 20 to 30 mL/kg of crystalloids and adequate alkalinization, a direct-acting alpha-1 agonist must be initiated immediately. Norepinephrine (titrated from 2 to 30 mcg/min) is the primary first-line vasopressor. It directly stimulates peripheral alpha-1 receptors, overcoming competitive TCA antagonism and restoring systemic vascular resistance (SVR).
4. Why Not Dopamine: Dopamine is a poor choice in severe cyclic antidepressant shock. It acts largely indirectly, by releasing presynaptic norepinephrine, and those stores may be depleted by prolonged reuptake blockade, so its pressor effect is unreliable. At low infusion rates its dopaminergic (DA1) effects can also cause vasodilation. A direct-acting agent such as norepinephrine is preferred.

---

Critical Contraindications and Second-Line Resuscitation

Lethal Drug Contraindications

• Physostigmine is Absolutely Contraindicated: Although physostigmine reverses anticholinergic delirium by inhibiting acetylcholinesterase, its use in cyclic antidepressant overdose has precipitated severe bradycardia, complete atrioventricular block, refractory asystole, and cardiac arrest. The conduction delays from fast sodium channel blockade render the myocardium exquisitely sensitive to physostigmine-induced vagal surge.
• Class IA and IC Antiarrhythmics are Absolutely Contraindicated: Agents such as procainamide, quinidine, disopyramide (Class IA), and flecainide or propafenone (Class IC) are potent myocardial fast sodium channel blockers. Administering them in TCA overdose compounds channel inhibition, precipitating irreversible widening of the QRS complex, fatal ventricular dysrhythmias, and electromechanical dissociation.
• Class III Antiarrhythmics: Amiodarone and sotalol prolong Phase 3 repolarization and the QT interval, compounding TCA-induced IKr blockade and increasing the risk of degenerate polymorphic ventricular tachycardia.

Second-Line and Rescue Therapies

• Lidocaine (Class IB): Lidocaine is a rapidly dissociating, use-dependent sodium channel blocker. In patients with refractory ventricular tachycardia where sodium bicarbonate and hypertonic saline have been maximized, lidocaine (1 to 1.5 mg/kg IV push) can competitively displace the more slowly dissociating TCA molecules from the Nav1.5 binding site without prolonging repolarization.
• Intravenous Lipid Emulsion (ILE / 20% Intralipid): For refractory cardiovascular collapse or cardiac arrest unresponsive to standard resuscitation, 20% lipid emulsion serves as a rescue modality. It acts primarily as a intravascular "lipid sink," sequestering lipophilic cyclic antidepressant molecules away from target myocardial receptors, while augmenting cardiac myocyte fatty acid metabolism and intracellular calcium availability.